Hepatitis C: global epidemiology and strategies for control.

[1]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[2]  P. Maisonneuve,et al.  Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. , 2016, Journal of hepatology.

[3]  H. Luma,et al.  Characteristics of anti-hepatitis C virus antibody-positive patients in a hospital setting in Douala, Cameroon. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[4]  P. Böelle,et al.  Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta‐analysis , 2016, Journal of viral hepatitis.

[5]  A. Thompson.  Australian recommendations for the management of hepatitis C virus infection: a consensus statement , 2016, The Medical journal of Australia.

[6]  G. Ippolito,et al.  Liver transplant recipients and prioritization of anti‐HCV therapy: an Italian cohort analysis , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[7]  J. Kao,et al.  Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection , 2016, Hepatology International.

[8]  C. Sabin,et al.  Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. V. van Kasteren,et al.  Acute hepatitis C in the Netherlands: characteristics of the epidemic in 2014. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[10]  M. Iqbal,et al.  Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data. , 2016, World journal of gastroenterology.

[11]  P. Tovo,et al.  Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression. , 2016, World journal of gastroenterology.

[12]  T. Asselah,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.

[13]  J. Ward,et al.  Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs. , 2015, The New England journal of medicine.

[14]  K. Reddy,et al.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. , 2015, The New England journal of medicine.

[15]  T. Berg,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. , 2015, The New England journal of medicine.

[16]  R. Malekzadeh,et al.  Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 3 , 2015, Journal of viral hepatitis.

[17]  A. Hatzakis,et al.  Estimating HCV disease burden – volume 3 (editorial) , 2015, Journal of viral hepatitis.

[18]  N. Shire,et al.  Epidemiology of Hepatitis C Virus: A Battle on New Frontiers. , 2015, Gastroenterology clinics of North America.

[19]  C. Stedman,et al.  Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. , 2015, Gastroenterology.

[20]  A. Chaturvedi,et al.  Epidemiological Profile of Hepatitis C Patients at India's New Hub -Haryana , 2015 .

[21]  Associates.,et al.  Egypt Health Issues Survey 2015 , 2015 .

[22]  D. Dieterich,et al.  Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. , 2015, The New England journal of medicine.

[23]  R. Geskus,et al.  Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control Study , 2015, Open forum infectious diseases.

[24]  Aasld Idsa Hcv Guidance Panel.  Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.

[25]  Y. Yazdanpanah,et al.  How to optimize hepatitis C virus treatment impact on life years saved in resource‐constrained countries , 2015, Hepatology.

[26]  Dan J Stein,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[27]  M. Nelson,et al.  Acute hepatitis C infection in HIV‐negative men who have sex with men , 2015, Journal of viral hepatitis.

[28]  A. Luke,et al.  High frequency of active HCV infection among seropositive cases in west Africa and evidence for multiple transmission pathways. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  Jason Grebely,et al.  Mixed HCV infection and reinfection in people who inject drugs—impact on therapy , 2015, Nature Reviews Gastroenterology &Hepatology.

[30]  Jagpreet Chhatwal,et al.  Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States , 2015, Annals of Internal Medicine.

[31]  E. El-Ghitany,et al.  A comprehensive hepatitis C virus risk factors meta‐analysis (1989–2013); Do they differ in Egypt? , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[32]  G. Ippolito,et al.  Is hepatitis C virus eradication around the corner only 25 years after its discovery? , 2015, International journal of antimicrobial agents.

[33]  L. Abu-Raddad,et al.  Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt , 2015, Hepatology.

[34]  M. Leshno,et al.  Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2 , 2015, Journal of viral hepatitis.

[35]  F. Negro.  Epidemiology of hepatitis C in Europe. , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[36]  Shymaa E. Bilasy,et al.  Prior to the Oral Therapy, What Do We Know About HCV-4 in Egypt: A Randomized Survey of Prevalence and Risks Using Data Mining Computed Analysis , 2014, Medicine.

[37]  H. Innes,et al.  Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? , 2014, Gut.

[38]  G. Dusheiko,et al.  Natural history of hepatitis C. , 2014, Journal of hepatology.

[39]  H. Razavi,et al.  Global epidemiology and genotype distribution of the hepatitis C virus infection. , 2014, Journal of hepatology.

[40]  B. Edlin,et al.  Can hepatitis C be eradicated in the United States? , 2014, Antiviral research.

[41]  K. Peltekian.  With all the new treatment regimens, complete elimination of hepatitis C virus in Canada is a possibility! But when will Canadians have access these drugs? , 2014, Canadian journal of gastroenterology & hepatology.

[42]  S. Hutchinson,et al.  Rapid Decline in HCV Incidence among People Who Inject Drugs Associated with National Scale-Up in Coverage of a Combination of Harm Reduction Interventions , 2014, PloS one.

[43]  Janet J. Hamilton,et al.  Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  J. F. Djoba Siawaya,et al.  The risk of transfusion-transmitted viral infections at the Gabonese National Blood Transfusion Centre. , 2014, Blood transfusion = Trasfusione del sangue.

[45]  L. Abu-Raddad,et al.  Vertical Transmission of Hepatitis C Virus: Systematic Review and Meta-analysis , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  L. Valiquette,et al.  Evolution of the Global Burden of Viral Infections from Unsafe Medical Injections, 2000–2010 , 2014, PloS one.

[47]  J. Ward,et al.  Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward) , 2014, Journal of viral hepatitis.

[48]  M. Sherman,et al.  Burden of disease and cost of chronic hepatitis C virus infection in Canada , 2014 .

[49]  C. Rice,et al.  Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resource , 2013, Hepatology.

[50]  N. Kamal,et al.  Burden of pediatric hepatitis C. , 2013, World journal of gastroenterology.

[51]  N. Ibeziako,et al.  Prevalence and risk factors for hepatitis C and human immunodeficiency virus coinfection among children in enugu, Nigeria. , 2013, African journal of infectious diseases.

[52]  A. Flaxman,et al.  Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.

[53]  M. Alter,et al.  Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study , 2013, Hepatology.

[54]  R. Chou,et al.  Reducing Risk for Mother-to-Infant Transmission of Hepatitis C Virus: A Systematic Review for the U.S. Preventive Services Task Force , 2013, Annals of Internal Medicine.

[55]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[56]  R. Pouillot,et al.  Phylogeography, Risk Factors and Genetic History of Hepatitis C Virus in Gabon, Central Africa , 2012, PloS one.

[57]  M. Kretzschmar,et al.  Estimating the force of infection for HCV in injecting drug users using interval-censored data , 2011, Epidemiology and Infection.

[58]  G. Ippolito,et al.  Molecular epidemiology of a hepatitis C virus epidemic in a haemodialysis unit: outbreak investigation and infection outcome , 2010, BMC infectious diseases.

[59]  K. Nelson,et al.  Prevalence of and risk factors for hepatitis B and C infection among Mongolian blood donors , 2010, Transfusion.

[60]  Y. Khudyakov,et al.  Transmission of hepatitis C virus in an orthopedic hospital ward , 2009, Journal of medical virology.

[61]  K. Nelson,et al.  Prevalence of HCV and genotypes distribution in general population of Georgia. , 2008, Georgian medical news.

[62]  G. Rezza,et al.  Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis , 2008, Journal of Epidemiology & Community Health.

[63]  D. Heymann.  Control, elimination, eradication and re-emergence of infectious diseases: getting the message right. , 2006, Bulletin of the World Health Organization.

[64]  J. Parry,et al.  Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study , 2004, BMJ : British Medical Journal.

[65]  B. Aylward,et al.  When is a disease eradicable? 100 years of lessons learned. , 2000, American journal of public health.

[66]  J. Parry,et al.  Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey , 2000, BMJ : British Medical Journal.

[67]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[68]  J. Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2015. , 2015, Journal of hepatology.

[69]  D. Rein,et al.  Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[70]  X. Forns,et al.  Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. , 2008, Journal of hepatology.

[71]  V. de Lédinghen,et al.  Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). , 2007, Journal of hepatology.

[72]  L. Simonsen,et al.  Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. , 1999, Bulletin of the World Health Organization.

[73]  W. Dowdle.  The principles of disease elimination and eradication. , 1998, Bulletin of the World Health Organization.